PARIS, FRANCE, January 15 28, 2025 – Qynapse congratulates Anavex Life Sciences on the peer-reviewed publication of the ANAVEX®2-73-AD-004 Phase IIb/III clinical trial in The Journal of Prevention of Alzheimer’s Disease. This 48-week randomized, placebo-controlled study demonstrated that oral blarcamesine (ANAVEX®2-73) significantly slowed cognitive and functional decline in individuals with early Alzheimer’s disease.
We are proud to have contributed to this milestone by providing the comprehensive brain MRI analysis using our advanced neuroimaging platform QyScore®. Our analysis confirmed a significant reduction in whole brain atrophy and lateral ventricle enlargement in patients receiving blarcamesine, compared to the placebo group, further indicating a neuroprotective treatment effect. Key findings from the study include:
- A 36.3% reduction on ADAS-Cog13 decline and a 27.6% reduction on CDR-SB decline, compared to placebo, demonstrating treatment was associated with a reduction in clinical and cognitive decline.
- A significant increase in the plasma Aβ42/40 ratio (p = 0.048), consistent with reduced brain amyloid burden.
- A significant attenuation of whole brain volume loss measured by MRI (p = 0.002), quantified through QyScore®.
These outcomes underscore the value of neuroimaging biomarkers in demonstrating disease-modifying effects in Alzheimer’s disease trials. Qynapse is honored to support cutting-edge research with validated, fully-automated MRI quantification and remains committed to advancing precision neurology.
https://doi.org/10.1016/j.tjpad.2024.100016
About Qynapse: Qynapse SAS is a medical technology company commercializing an AI-powered and proprietary neuroimaging software platform, creating the potential for earlier clinical precision on the frontlines of CNS disease. Qynapse’s flagship solution, QyScore®, FDA-Cleared and CE-Marked, adds the potential for more precise and objective brain scan analysis. Qynapse is headquartered in France with offices in the US Canada. www.qynapse.com